These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 36225496)
21. Therapeutic Options for Metallo-β-Lactamase-Producing Enterobacterales. Tan X; Kim HS; Baugh K; Huang Y; Kadiyala N; Wences M; Singh N; Wenzler E; Bulman ZP Infect Drug Resist; 2021; 14():125-142. PubMed ID: 33500635 [TBL] [Abstract][Full Text] [Related]
22. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae? Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541 [TBL] [Abstract][Full Text] [Related]
23. In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula. Sonnevend Á; Ghazawi A; Darwish D; Barathan G; Hashmey R; Ashraf T; Rizvi TA; Pál T Int J Infect Dis; 2020 Oct; 99():253-259. PubMed ID: 32738488 [TBL] [Abstract][Full Text] [Related]
24. Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019-2020). Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Castanheira M Eur J Clin Microbiol Infect Dis; 2022 Mar; 41(3):477-487. PubMed ID: 35041100 [TBL] [Abstract][Full Text] [Related]
25. Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales. Falcone M; Daikos GL; Tiseo G; Bassoulis D; Giordano C; Galfo V; Leonildi A; Tagliaferri E; Barnini S; Sani S; Farcomeni A; Ghiadoni L; Menichetti F Clin Infect Dis; 2021 Jun; 72(11):1871-1878. PubMed ID: 32427286 [TBL] [Abstract][Full Text] [Related]
27. Management of serious infections caused by metallo β-lactamases with or without OXA-48-like expressing Enterobacterales with aztreonam and ceftazidime/avibactam combination: Dosing strategy for better clinical outcome. Veeraraghavan B; Bakthavatchalam YD; Soman R; Swaminathan S; Manesh A; Nagvekar V; Nangia V Indian J Med Microbiol; 2021 Jul; 39(3):286-288. PubMed ID: 33892973 [TBL] [Abstract][Full Text] [Related]
28. Novel case of combination antibiotic therapy for treatment of a complicated polymicrobial urinary tract infection with one organism harboring a metallo-β-lactamase (MBL) in a pregnant patient. Ruddy S; Bapna M; Karnik K; Yung L; Rodriguez G; Urban C; Yoon J; Prasad N; Segal-Maurer S; Turett G IDCases; 2024; 36():e01946. PubMed ID: 38646598 [TBL] [Abstract][Full Text] [Related]
29. Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1. Yasmin M; Fouts DE; Jacobs MR; Haydar H; Marshall SH; White R; D'Souza R; Lodise TP; Rhoads DD; Hujer AM; Rojas LJ; Hoyen C; Perez F; Edwards A; Bonomo RA Clin Infect Dis; 2020 Aug; 71(4):1095-1098. PubMed ID: 31802119 [TBL] [Abstract][Full Text] [Related]
30. In vitro activity of ceftazidime/avibactam against Gram-negative strains in Colombia 2014-2018. Lemos-Luengas EV; Rentería-Valoyes S; Cárdenas-Isaza P; Ramos-Castaneda JA J Glob Antimicrob Resist; 2022 Jun; 29():141-146. PubMed ID: 35257971 [TBL] [Abstract][Full Text] [Related]
31. Sulfamoyl Heteroarylcarboxylic Acids as Promising Metallo-β-Lactamase Inhibitors for Controlling Bacterial Carbapenem Resistance. Wachino JI; Jin W; Kimura K; Kurosaki H; Sato A; Arakawa Y mBio; 2020 Mar; 11(2):. PubMed ID: 32184250 [TBL] [Abstract][Full Text] [Related]
32. Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae. Maraki S; Mavromanolaki VE; Moraitis P; Stafylaki D; Kasimati A; Magkafouraki E; Scoulica E Eur J Clin Microbiol Infect Dis; 2021 Aug; 40(8):1755-1759. PubMed ID: 33595756 [TBL] [Abstract][Full Text] [Related]
33. Ceftazidime/Avibactam and Other Commonly Used Antibiotics Activity Against Enterobacterales and Zalas-Więcek P; Prażyńska M; Pojnar Ł; Pałka A; Żabicka D; Orczykowska-Kotyna M; Polak A; Możejko-Pastewka B; Głowacka EA; Pieniążek I; Pawlik M; Grys M; Bogiel M Infect Drug Resist; 2022; 15():1289-1304. PubMed ID: 35370409 [TBL] [Abstract][Full Text] [Related]
34. In vitro activity of aztreonam/avibactam against isolates of Enterobacterales collected globally from ATLAS in 2019. Rossolini GM; Stone G; Kantecki M; Arhin FF J Glob Antimicrob Resist; 2022 Sep; 30():214-221. PubMed ID: 35760303 [TBL] [Abstract][Full Text] [Related]
35. In vitro susceptibilities of isolates of potentially naturally inducible chromosomal AmpC-producing metallo-β-lactamase-negative carbapenem-resistant Enterobacterales species to ceftazidime-avibactam: Data from the Antimicrobial Testing Leadership and Surveillance Programme, 2012-2019. Jean SS; Lee YL; Hsu CW; Hsueh PR Int J Antimicrob Agents; 2022 Sep; 60(3):106617. PubMed ID: 35718266 [TBL] [Abstract][Full Text] [Related]
36. Success of ceftazidime-avibactam and aztreonam in combination for a refractory biliary infection with recurrent bacteraemia due to McKew G; Merlino J; Beukers A; van Hal S; Gottlieb T Access Microbiol; 2021; 3(8):000248. PubMed ID: 34888479 [TBL] [Abstract][Full Text] [Related]
37. Wang W; Huang S; Zou C; Ding Y; Wang H; Pu S; Liao Y; Du H; Wang D; Chen L; Niu S Front Cell Infect Microbiol; 2021; 11():755763. PubMed ID: 34778107 [TBL] [Abstract][Full Text] [Related]
38. Selection and characterization of mutational resistance to aztreonam/avibactam in β-lactamase-producing Enterobacterales. Mushtaq S; Vickers A; Ellaby N; Woodford N; Livermore DM J Antimicrob Chemother; 2021 Dec; 77(1):98-111. PubMed ID: 34568905 [TBL] [Abstract][Full Text] [Related]
39. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values. Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206 [TBL] [Abstract][Full Text] [Related]